Q3 EPS Estimates for Journey Medical Raised by Roth Capital

Journey Medical Co. (NASDAQ:DERM - Free Report) - Equities research analysts at Roth Capital upped their Q3 2025 EPS estimates for shares of Journey Medical in a research report issued on Thursday, March 27th. Roth Capital analyst J. Wittes now anticipates that the company will post earnings of $0.10 per share for the quarter, up from their prior estimate of $0.09. The consensus estimate for Journey Medical's current full-year earnings is ($1.02) per share. Roth Capital also issued estimates for Journey Medical's Q4 2025 earnings at $0.16 EPS and FY2029 earnings at $5.83 EPS.

Journey Medical (NASDAQ:DERM - Get Free Report) last posted its quarterly earnings data on Wednesday, March 26th. The company reported $0.08 EPS for the quarter, topping the consensus estimate of ($0.22) by $0.30. Journey Medical had a negative net margin of 31.74% and a negative return on equity of 132.10%. The company had revenue of $14.30 million during the quarter, compared to analyst estimates of $14.21 million.

Separately, Alliance Global Partners restated a "buy" rating on shares of Journey Medical in a research note on Thursday, March 27th. Four research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, Journey Medical presently has an average rating of "Buy" and an average price target of $9.67.

Journey Medical Trading Up 0.6 %

Shares of NASDAQ DERM traded up $0.04 during mid-day trading on Friday, reaching $5.94. The company had a trading volume of 21,837 shares, compared to its average volume of 86,026. The stock has a market cap of $124.00 million, a price-to-earnings ratio of -6.32 and a beta of 0.97. Journey Medical has a 52 week low of $3.20 and a 52 week high of $6.89. The business's 50-day moving average is $5.14 and its 200-day moving average is $5.18. The company has a current ratio of 1.38, a quick ratio of 1.03 and a debt-to-equity ratio of 1.81.

Insider Transactions at Journey Medical

In related news, CEO Claude Maraoui sold 49,271 shares of the firm's stock in a transaction dated Tuesday, March 11th. The stock was sold at an average price of $5.01, for a total transaction of $246,847.71. Following the sale, the chief executive officer now directly owns 2,003,147 shares of the company's stock, valued at $10,035,766.47. This trade represents a 2.40 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have sold 105,831 shares of company stock worth $536,622 over the last 90 days. 13.16% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Tang Capital Management LLC purchased a new position in shares of Journey Medical in the 4th quarter valued at about $6,747,000. PVG Asset Management Corp grew its holdings in Journey Medical by 5.7% in the third quarter. PVG Asset Management Corp now owns 167,545 shares of the company's stock valued at $947,000 after purchasing an additional 9,005 shares during the period. Geode Capital Management LLC increased its position in shares of Journey Medical by 13.5% in the third quarter. Geode Capital Management LLC now owns 108,435 shares of the company's stock valued at $613,000 after buying an additional 12,882 shares in the last quarter. Citadel Advisors LLC acquired a new position in shares of Journey Medical during the 4th quarter worth approximately $174,000. Finally, Kovitz Investment Group Partners LLC lifted its position in shares of Journey Medical by 112.9% during the 4th quarter. Kovitz Investment Group Partners LLC now owns 24,710 shares of the company's stock valued at $97,000 after buying an additional 13,105 shares in the last quarter. Hedge funds and other institutional investors own 7.25% of the company's stock.

About Journey Medical

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.